Study Links E-Cigarette Bans to Increased Cigarette Sales

Apr.08.2022
Study Links E-Cigarette Bans to Increased Cigarette Sales
A new study suggests that state-level e-cigarette bans are associated with increased cigarette sales.

According to foreign media reports, a new study suggests that a national ban on e-cigarettes is linked to an increase in cigarette sales. The study, published in the scientific journal "Health Affairs," adds to mounting evidence that banning the sale of e-cigarettes may lead more people to revert back to smoking, which is less safe than using nicotine alternatives.

 

During a three-month study, it was found that an additional 3.4 million cigarette packs were sold through convenience stores across three states.

 

Researchers have used state-level cigarette sales data to discover that Massachusetts, which has implemented a complete ban on nicotine e-cigarettes, has seen a 7.5% increase in per capita cigarette sales compared to expectations. Rhode Island and Washington, which have enacted bans on non-tobacco flavored nicotine e-cigarettes, have an average estimated increase of 4.6% in per capita cigarette sales compared to expectations. Based on actual and estimated cigarette sales, the researchers suggest that an additional 3.4 million cigarette packs were sold in convenience stores across the three states during the three-month study period following the implementation of their respective bans.

 

The study was sponsored by Juul Labs, but has had little impact thus far, possibly due to the belief among many in the tobacco control field that research funded by the industry is biased. This debate may stem from decades of data suppression by big tobacco companies, which has recently resurfaced. For example, the Society for Research on Nicotine and Tobacco (SRNT) now explicitly prohibits industry-sponsored speakers from presenting at its conferences, a move that has led to resignations and condemnation of current tobacco control as "anti-scientific".

 

Researchers examined data from the fall of 2019, when legislators began paying attention to a series of mysterious lung diseases referred to as EVALI, which were quickly associated with e-cigarettes by politicians. Although by November 2019, the Centers for Disease Control and Prevention (CDC) had attributed most cases to contaminated illegal THC cartridges, state governments still stirred up panic and sought emergency bans, which in some cases became permanent.

 

In response to the EVALI outbreak, Massachusetts instituted an emergency ban on all nicotine e-cigarettes starting on September 24, 2019. Rhode Island and Washington followed suit, implementing four-month emergency bans on non-tobacco flavored nicotine e-cigarettes on October 4, 2019, and October 10, 2019, respectively. Massachusetts has since permanently banned the sale of flavored e-cigarette products, including menthol, while Rhode Island and Washington's emergency bans have expired, though a permanent flavor ban remains on the table.

 

Previous research has found similar results to those presented in health value papers.

 

The use of nicotine has not been linked to any diagnosis of EVALI in the field of medicine, but misinformation continues to spread. Under the guidance of sensationalist reporting by policymakers and the media, concerns over the rates of youth vaping have directly sparked fears over deadly vaping products. Misleading information is simple: youth are using e-cigarettes and, in some cases, dying from them. Over two years have passed since the outbreak, and the Centers for Disease Control and Prevention (CDC) in the US have yet to release any formal correction stating that nicotine e-cigarettes are not associated with lung injuries.

 

Previous research has yielded similar results to the findings of a health-focused paper. Co-authors from Boston University published an article in the Harm Reduction Journal indicating that misunderstandings surrounding EVALI (e-cigarette or vaping product use-associated lung injury) – which led to a ban in Massachusetts – appeared to have increased cigarette consumption across Boston. Moreover, Dr. Abigail Friedman from Yale University found in JAMA Pediatrics that after San Francisco banned flavored e-cigarettes and tobacco products, high schoolers in the city were more likely to smoke than their peers in other similar districts across the US.

 

(Source: Filter)

 

Restrictions on vaping products may have unintended consequences, including an increase in cigarette sales. While policymakers have focused on limiting access to e-cigarettes, they may inadvertently be pushing consumers back to traditional tobacco products. This is especially problematic given the well-documented health risks associated with smoking. It remains to be seen whether tighter regulations on vaping will have the intended impact of reducing nicotine addiction overall.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Ireland’s Vape Tax Raises €22 Million in Nine Months as Government Considers 2027 Budget Changes
Ireland’s Vape Tax Raises €22 Million in Nine Months as Government Considers 2027 Budget Changes
According to Irish media outlets Highland Radio and BreakingNews.ie, the Irish government is considering whether to adjust vape tax policy in the 2027 Budget. The tax has generated about €22 million ($24 million) in revenue during its first nine months. While no increase has been confirmed, the revenue performance could influence future fiscal discussions. Any tax rise could increase product costs and potentially affect retail prices.
Aug.12
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
Philip Morris International's PMI Business Solutions Philippines has expanded its global business services hub in Makati and plans to add more than 80 positions. Established in 2021 primarily to provide finance and IT support to about 20 markets, the center now employs 519 professionals delivering roughly 600 services across 160 markets. Its functions now span finance, human resources, IT, commercial operations, data analytics, supply chain and project management. PMI says the hub's next phase will focus on AI-enabled and higher-value work. The company did not disclose the size or investment cost of the expansion.
Sep.24
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan Industrial Co., Ltd. has filed a patent application for a cellulose-free scaffold material for nicotine pouches, proposing a combination of bioceramic material, polydextrose and sugar alcohols to replace conventional microcrystalline cellulose and cellulose derivatives. The filing aims to address issues including powdery mouthfeel, residue and limited release control, while also reducing reliance on existing cellulose-based patent portfolios. In patent examples, one fast-release formulation reached a nicotine release rate of 50% at 10 minutes and more than 90% at 20 minutes.
Sep.02
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07